6-Ethyl-2,2-dimethyloctane-3,5-dione | 188530-39-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Ethyl-2,2-dimethyloctane-3,5-dione
• CAS: 188530-39-4
• 化学式: C₁₂H₂₂O₂
• 分子量: 198.3
• InChiKey: GPOXCFJNNXDRSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Bna Conjugates and Methods of Use
  申请人：James Kenneth D.

  公开号：US20080207505A1

  公开（公告）日：2008-08-28

  Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the hBNP compound are also disclosed, having an amino acid sequence that is other than the native sequence.

  本发明公开了改性利钠肽化合物及其共轭物。具体而言，提供了至少连接有一个修饰基团的hBNP的共轭形式。这些改性利钠肽化合物共轭物保留了刺激cGMP产生、结合NPR-A受体、降低动脉血压以及在某些实施例中相对于未经改性的对应利钠肽化合物具有改善的循环半衰期的活性。这些化合物和共轭物的口服、静脉注射、肠内、皮下、肺部和静脉形式可作为治疗和/或治疗心脏病症，特别是充血性心力衰竭的治疗。还公开了包含具有各种长度和构型的寡聚结构的修饰基团。此外，还公开了hBNP化合物的类似物，其氨基酸序列与天然序列不同。
• FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF
  申请人：Radhakrishnan Balasingam

  公开号：US20100105605A1

  公开（公告）日：2010-04-29

  Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.

  脂肪酸组成用于制备药物，例如蛋白质和肽，蛋白质和肽共轭物和/或阳离子-多肽共轭物复合物的给药。特别地，本发明提供一种固体制剂，用于口服给药，含有约0.1至约75% w/w的脂肪酸成分，其中脂肪酸成分包括饱和或不饱和的C4、C5、C6、C7、C8、C9、C10、C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。此外，本发明提供一种液体制剂，用于口服给药，包括：约0.1至约10% w/v的脂肪酸成分，其中脂肪酸成分包括饱和或不饱和的C4、C5、C6、C7、C8、C9、C10、C11或C12脂肪酸和/或这些脂肪酸的盐；以及治疗剂。
• JPH09111454A
  申请人：——

  公开号：JPH09111454A

  公开（公告）日：1997-04-28
• NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF
  申请人：James Kenneth D.

  公开号：US20100216714A1

  公开（公告）日：2010-08-26

  Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.
• MATERIAL FOR CHEMICAL VAPOR DEPOSITION AND PROCESS FOR FORMING SILICON-CONTAINING THIN FILM USING SAME
  申请人：Sato Hiroki

  公开号：US20120021127A1

  公开（公告）日：2012-01-26

  A material for chemical vapor deposition containing an organic silicon-containing compound represented by formula: HSiCl(NR 1 R 2 )(NR 3 R 4 ), wherein R 1 and R 3 each represent C1-C4 alkyl or hydrogen; and R 2 and R 4 each represent C1-C4 alkyl. The material is particularly suitable as a material for forming a silicon nitride thin film on a substrate by chemical vapor deposition. The use of the material allows for film formation at low temperatures ranging from 300° to 500° C.